Register
Login:
Share:
Email Facebook Twitter

RNS VIDEO: Reabold Resources #RBD raise £6 million and take stake in Danube Petroleum Watch here

EXCLUSIVE: HemoGenyx are creating blood cancer treatments with US$9 billion market potential


Astrazeneca Share News (AZN)

Stock Market news at lse.co.uk - RSS News Feeds

Share News for Astrazeneca (AZN)


Share Price: 4,881.00Bid: 4,881.00Ask: 4,884.50Change: 0.00 (0.00%)No Movement on Astrazeneca
Spread: 3.50Spread as %: 0.07%Open: 4,889.00High: 4,889.00Low: 4,846.50Yesterday’s Close: 4,881.00






Bumper crop of new drugs fails to lift big pharma R&D returns

* 41 FDA drug approvals so far in 2017 vs 22 for all 2016* Biotech companies account for growing share* Deloitte says big pharma returns on R&D just 3
[14 Dec '17 00:01]

UPDATE 1-Companies prepare for disorderly Brexit as talks stall

* Transition deal comes too late for banks* Retailers identifying alternative suppliers* Manufacturers struggling to plan (Adds CBI quote)By Kate Holt
[7 Dec '17 09:57]

Companies prepare for disorderly Brexit as talks stall

* Transition deal comes too late for banks* Retailers identifying alternative suppliers* Manufacturers struggling to planBy Kate Holton and Andrew Mac
[7 Dec '17 06:00]

UPDATE 1-GSK, other drugmakers bet on post-Brexit UK science

(Adds details on more companies)By Ben HirschlerLONDON, Dec 6 (Reuters) - Britain won a vote of confidence from its economically important life scienc
[6 Dec '17 12:16]

GSK, other drugmakers bet on post-Brexit UK science

LONDON, Dec 6 (Reuters) - Britain won a vote of confidence from its economically important life sciences sector on Wednesday as five drug companies co
[6 Dec '17 00:01]

BUZZ-Circassia Pharmaceuticals: jumps on positive Tudorza data

** Circassia Pharmaceuticals up 2.2 pct -- having jumped as much as 12.7 pct in early trade to the top of FTSE Small Cap index** Circassia and AstraZe
[4 Dec '17 10:10]

UPDATE 1-Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial

* JAVELIN Gastric 300 trial misses primary goal* Bavencio already approved in skin, bladder cancer types* Results from use against lung cancer still o
[28 Nov '17 14:37]

UPDATE 2-Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial

* JAVELIN Gastric 300 trial misses primary goal* Bavencio already approved in skin, bladder cancer types* Results from use against lung cancer still o
[28 Nov '17 14:37]



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.